SG10201913978RA - Anti-mutated kras t cell receptors - Google Patents

Anti-mutated kras t cell receptors

Info

Publication number
SG10201913978RA
SG10201913978RA SG10201913978RA SG10201913978RA SG10201913978RA SG 10201913978R A SG10201913978R A SG 10201913978RA SG 10201913978R A SG10201913978R A SG 10201913978RA SG 10201913978R A SG10201913978R A SG 10201913978RA SG 10201913978R A SG10201913978R A SG 10201913978RA
Authority
SG
Singapore
Prior art keywords
cell receptors
mutated kras
kras
mutated
receptors
Prior art date
Application number
SG10201913978RA
Inventor
Qiong J Wang
Zhiya Yu
James C Yang
Original Assignee
The United States Of America As Represented By The Secretary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201462084654P priority Critical
Priority to US201562171321P priority
Application filed by The United States Of America As Represented By The Secretary filed Critical The United States Of America As Represented By The Secretary
Publication of SG10201913978RA publication Critical patent/SG10201913978RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001164GTPases, e.g. Ras, Rho
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
SG10201913978RA 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors SG10201913978RA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201462084654P true 2014-11-26 2014-11-26
US201562171321P true 2015-06-05 2015-06-05

Publications (1)

Publication Number Publication Date
SG10201913978RA true SG10201913978RA (en) 2020-03-30

Family

ID=54838442

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201704155UA SG11201704155UA (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors
SG10201913978RA SG10201913978RA (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201704155UA SG11201704155UA (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors

Country Status (16)

Country Link
US (1) US20170304421A1 (en)
EP (2) EP3666288A1 (en)
JP (1) JP2017536825A (en)
KR (1) KR20170099905A (en)
CN (1) CN107223134A (en)
AU (2) AU2015353720B2 (en)
CA (1) CA2968399A1 (en)
ES (1) ES2784261T3 (en)
HK (1) HK1243642A1 (en)
IL (1) IL252258D0 (en)
MX (1) MX2017006865A (en)
PL (1) PL3223850T3 (en)
PT (1) PT3223850T (en)
SG (2) SG11201704155UA (en)
SI (1) SI3223850T1 (en)
WO (1) WO2016085904A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998869A1 (en) 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-cw8 restricted mutated kras
WO2018026691A1 (en) * 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-kras-g12d t cell receptors
WO2018069871A2 (en) * 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
BR112020005469A2 (en) * 2017-09-20 2020-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services hla class ii restrictive t cell receptors against mutated ras
BR112020011111A2 (en) * 2017-12-04 2020-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services class i hla-restricted t cell receptors against mutated ras
WO2020154275A1 (en) * 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12r mutation
WO2020210202A1 (en) * 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709002B1 (en) * 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO315238B1 (en) * 1998-05-08 2003-08-04 Gemvax As Peptides derived from the reading frame shift mutations in TBF <beta> II or BAX gene, and pharmaceutical compositions containing these nucleic acid sequences encoding such peptides, plasmids and virusvektoreromfattende slikenukleinsy
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
EP2102236B1 (en) * 2007-01-12 2014-08-06 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services GP100-specific T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
CN102712953A (en) * 2009-09-17 2012-10-03 密歇根大学董事会 Recurrent gene fusions in prostate cancer
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN108395479A (en) * 2017-02-06 2018-08-14 高军 A kind of T cell receptor in relation to KRAS gene mutation

Also Published As

Publication number Publication date
AU2015353720B2 (en) 2020-02-27
PT3223850T (en) 2020-04-13
KR20170099905A (en) 2017-09-01
CN107223134A (en) 2017-09-29
ES2784261T3 (en) 2020-09-23
MX2017006865A (en) 2018-01-11
HK1243642A1 (en) 2018-07-20
SI3223850T1 (en) 2020-09-30
EP3666288A1 (en) 2020-06-17
PL3223850T3 (en) 2020-08-24
AU2015353720A1 (en) 2017-06-08
EP3223850A1 (en) 2017-10-04
JP2017536825A (en) 2017-12-14
US20170304421A1 (en) 2017-10-26
SG11201704155UA (en) 2017-06-29
AU2020203465A1 (en) 2020-06-18
EP3223850B1 (en) 2020-01-08
WO2016085904A1 (en) 2016-06-02
IL252258D0 (en) 2017-07-31
CA2968399A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
HRP20191704T1 (en) Multispecific antibodies
IL250583D0 (en) Anti-tigit antibodies
GB2531928B (en) Image-stitching for dimensioning
HK1217861A1 (en) Wifi-coordinated laa-lte
ZA201608378B (en) Improved t cell compositions
GB201817189D0 (en) Image-stitching for dimensioning
SG11201703403TA (en) Anti-tim-3 antibodies
IL274903D0 (en) Cell
SG11201703346PA (en) Anti-tim-3 antibodies
GB201410907D0 (en) No details
HK1246825A1 (en) Cell
GB201414823D0 (en) Multispecific antibodies
GB2528557B (en) Soundbar
PT3101756T (en) Charging system
GB201516146D0 (en) None
PT3097397T (en) Schienenmesssystem
AU361515S (en) Dishrack
SE538951C2 (en) gripdon
GB201404893D0 (en) Selfie - Stick
HK1257902A1 (en) T cell receptors recognizing hla-cw8 restricted mutated kras
HK1231632A1 (en) Battery
GB201516266D0 (en) None
GB201407805D0 (en) Battery condition determination
HUE045323T2 (en) Electrolyte solution
GB201507368D0 (en) Cell